姓名 | 職稱 | 持有股份 | 代表法人 |
---|---|---|---|
Lin,Yong-Xiang | Chairman | 5.73% | YONG JIANG INVESTMENT CO., LTD. |
YANG GUANG INVESTMENT CO., LTD. | Director | 3.52% | |
Chen,Jing-Ting | Director | 2.14% | Maxigen Biotech Inc. |
Gao,Zhen-Yi | Independent Director | 0.00% | |
Liao,Song-Yuan | Independent Director | 0.00% | |
Vacancy | Independent Director | ||
He,Shu-Min | Independent Director | 0.00% |
項目 | 2024 | 2023 | 2022 |
---|---|---|---|
Operating income | 7,240,266 | 8,015,649 | 7,432,514 |
Operating cost | 4,062,460 | 4,799,114 | 4,297,047 |
Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
Operating gross profit (loss) | 3,177,806 | 3,216,535 | 3,135,467 |
Unrealized profit (loss) on sales of goods | - | - | - |
Realized profit (loss) on sales of goods | - | - | - |
Operating gross profit (loss), net | 3,177,806 | 3,216,535 | 3,135,467 |
Operating expenses | 2,150,079 | 2,161,937 | 2,109,365 |
Other gain (loss), net | - | - | - |
Operating profit (loss) | 1,027,727 | 1,054,598 | 1,026,102 |
Non-operating income and expenses | 106,736 | 120,097 | 263,667 |
Net profit (loss) before tax | 1,134,463 | 1,174,695 | 1,289,769 |
Income tax expense (benefits) | 160,735 | 182,631 | 469,007 |
Net profit (loss) of ongoing business for the current period | 973,728 | 992,064 | 820,762 |
Profit (loss) of closed units | - | - | - |
Profit (loss) of non-jointly controlled equity before merger | - | - | - |
Net profit (loss) for the current period | 973,728 | 992,064 | 820,762 |
Other comprehensive profit (loss), net | 131,619 | -81,883 | 93,958 |
Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
Total comprehensive profit and loss for the current period | 1,105,347 | 910,181 | 914,720 |
Net profit (loss) attributable to owners of parent company | 851,499 | 896,258 | 713,494 |
Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
Net profit (loss) attributable to non-controlling interests | 122,229 | 95,806 | 107,268 |
Comprehensive profit (loss) attributable to owners of parent company | 981,148 | 806,835 | 801,964 |
Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
Comprehensive profit (loss) attributable to non-controlling interests | 124,199 | 103,346 | 112,756 |
Basic earnings per share (yuan) | 7 | 7 | 6 |
項目 | 2024 | 2023 | 2022 |
---|---|---|---|
Net cash inflow (outflow) from operating activities | 1,480,562 | 1,905,226 | 955,636 |
Net cash inflows (outflows) from investing activities | -810,511 | -377,959 | 488,535 |
Net cash inflow (outflow) from financing activities | -1,227,668 | -1,973,702 | -832,616 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | -38,597 | -122,933 | 86,811 |
Increase (decrease) in cash and cash equivalents in the current period | -596,214 | -569,368 | 698,366 |
Beginning balance of cash and cash equivalents | 5,363,426 | 5,932,794 | 4,704,397 |
Ending balance of cash and cash equivalents | 4,767,212 | 5,363,426 | 5,402,763 |
項目 | 2024 | 2023 | 2022 |
---|---|---|---|
Current asset | 7,681,936 | 7,885,412 | 8,071,294 |
Non-current asset | 6,032,809 | 6,216,091 | 7,036,663 |
Total asset | 13,714,745 | 14,101,503 | 15,107,957 |
Current liability | 2,825,526 | 3,280,013 | 4,491,067 |
Non-current liability | 1,401,043 | 943,548 | 537,866 |
Total liability | 4,226,569 | 4,223,561 | 5,028,933 |
share capital | 1,182,608 | 1,182,608 | 1,182,608 |
Equity - secruity token | - | - | - |
capital reserve | 2,893,400 | 2,900,420 | 2,887,265 |
retained earning | 4,684,018 | 4,656,525 | 4,351,565 |
Other equity | -153,980 | -283,533 | -194,104 |
Treasury stock | -509,948 | -232,963 | -118,787 |
Total equity attributable to owners of parent company | 8,096,098 | 8,223,057 | 8,108,547 |
Equity attributable to former owner of business combination under common control | - | - | - |
Equity attributable to non-controlling interest before business merger under common control | - | - | - |
Non-controlling interests | 1,392,078 | 1,654,885 | 1,970,477 |
Total Equity | 9,488,176 | 9,877,942 | 10,079,024 |
Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 7,563,000 | 3,063,000 | 532,000 |
Net asset value per share | 73 | 71 | 68 |
標案名稱 | 機關名稱 | 決標日期 | 決標金額 | 是否得標 |
---|---|---|---|---|
台酒生技葉黃素軟膠囊瓶裝及體驗包議價案 | 臺灣菸酒股份有限公司屏東酒廠 | 107/08/22 | 是 | |
375159-12台酒生技深海魚油軟膠囊15000瓶議價案 | 臺灣菸酒股份有限公司屏東酒廠 | 105/11/23 | 是 | |
385104-12台酒生技葡萄糖胺複方錠15,000瓶議價案 | 臺灣菸酒股份有限公司屏東酒廠 | 105/11/23 | 是 | |
多元茄紅南瓜子油軟膠囊議價案 | 臺灣菸酒股份有限公司屏東酒廠 | 105/11/04 | 是 | |
台酒生技葉黃素軟膠囊瓶裝及體驗包議價案 | 臺灣菸酒股份有限公司屏東酒廠 | 105/10/19 | 是 | |
強關錠4,000瓶增購案 | 臺灣菸酒股份有限公司桃園酒廠 | 105/01/27 | 是 | |
台酒生技深海魚油膠囊5,000瓶增購 | 臺灣菸酒股份有限公司桃園酒廠 | 105/01/19 | 是 | |
台酒生技深海魚油膠囊5,000瓶購置案 | 臺灣菸酒股份有限公司桃園酒廠 | 104/02/25 | 是 | |
強關錠4,000瓶購置 | 臺灣菸酒股份有限公司桃園酒廠 | 104/02/25 | 是 | |
強關錠4,000瓶購置 | 臺灣菸酒股份有限公司林口酒廠 | 103/03/11 | 是 | |
多元茄紅南瓜子油4,000盒購置 | 臺灣菸酒股份有限公司林口酒廠 | 102/11/20 | 否 |
日期 | 違反法規法條 | 罰鍰金額 |
---|---|---|
2024/04/09 | Paragraph 1, Article 6 of the Occupational Safety and Health Act | |
2024/04/08 | Paragraph 1, Article 24 of the Labor Standards Act | 50,000 |
2024/03/06 | Paragraph 1, Article 24 of the Labor Standards Act; Paragraph 2, Article 32 of the Labor Standards Act; Paragraph 1, Article 36 of the Labor Standards Act | 210,000 |
2024/01/08 | Paragraph 1, Article 6 of the Occupational Safety and Health Act | |
2019/11/04 | Paragraph 1, Article 23 of the Occupational Safety and Health Act | |
2019/11/04 | Paragraph 1, Article 22 of the Occupational Safety and Health Act | |
2018/12/04 | Paragraph 2, Article 32 of the Labor Standards Act; Paragraph 1, Article 36 of the Labor Standards Act |